Fresh analysis suggests that patients who discontinue popular weight-loss injections like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise programs.
Findings released in a major health publication demonstrates that while overweight individuals frequently drop a large proportion of their body weight while using the jabs, the weight is regained at an average rate of nearly a kilo each month once they quit.
"People using such treatments must be informed of the potential of fast rebound weight gain when the therapy ends," stated expert Dr. Susan Jebb.
Such speed of recovery suggests a reversion to pre-treatment weight within about a year and a half.
Weighing Approaches
The study, which looked at 37 of trials involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with conventional dieting.
Scientists point out that individuals who lose weight through diet and exercise typically see a slower weight regain—approximately 100 grams monthly—post-intervention.
Understanding the Rapid Rebound
Nutrition scientists suggest the mode of action of the drugs accounts for the amplified regain.
The injections imitate a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing the hormone concentrations far above than the body's typical production could lead to the system to produce less of its endogenous hormone, and could reduce sensitivity to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this GLP-1 'fix' means hunger is no longer kept in check, making overeating far more likely."
An Ongoing Condition?
Medical guidelines recommend the jabs for individuals with weight-linked medical conditions, alongside recommended diet and exercise modifications.
A number of clinicians contend that, considering the significant potential of relapse, the treatment should be considered long-term.
This perspective is supported by pharmaceutical companies, who note that the findings "highlight the chronic character of obesity," akin to managing conditions like diabetes.
User Experiences
Users who have discontinued the medication explain a sudden resurgence of cravings.
"I experienced a trigger that goes on and I was suddenly ravenous," described a patient.
This difficulty is worsened if users have not established lasting dietary or behavioural modifications during therapy.
Widespread Use
Survey data suggest that millions of people in the UK have tried these injections in the past year, with desire remaining high.
- Adoption is more common among females than men.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
Finally, experts caution that while these medications are effective tools for weight loss, they are not a permanent cure and lasting health benefits relies on combined behavioural changes.
